Menu
Search
|

Menu

Close
X

Alkermes Plc ALKS.OQ (NASDAQ Stock Exchange Global Select Market)

57.37 USD
+0.82 (+1.45%)
As of 2:39 PM GMT
chart
Previous Close 56.55
Open 56.67
Volume 12,158
3m Avg Volume 369,044
Today’s High 57.64
Today’s Low 56.67
52 Week High 71.22
52 Week Low 46.65
Shares Outstanding (mil) 153.66
Market Capitalization (mil) 7,913.33
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
903
FY16
746
FY15
628
EPS (USD)
FY17
-0.945
FY16
-1.378
FY15
-1.520
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
9.84
5.77
Price to Book (MRQ)
vs sector
6.58
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
23.51
16.52
LT Debt to Equity (MRQ)
vs sector
23.26
12.22
Return on Investment (TTM)
vs sector
-12.81
14.43
Return on Equity (TTM)
vs sector
-16.00
16.13

EXECUTIVE LEADERSHIP

Richard Pops
Chairman of the Board, Chief Executive Officer, Since 2011
Salary: $911,228.00
Bonus: --
Shane Cooke
President, Since 2011
Salary: $561,847.00
Bonus: --
James Frates
Chief Financial Officer, Senior Vice President, Treasurer, Since 2011
Salary: $499,741.00
Bonus: --
Kathryn Biberstein
Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Chief Risk Officer, Secretary, Since 2017
Salary: $523,052.00
Bonus: --
Elliot Ehrich
Executive Vice President - Science and Therapeutics, Since 2018
Salary: $533,704.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Connaught HSE, 1 Burlington Road
DUBLIN     00000

Phone: +3531.7728000

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

SPONSORED STORIES